ClinicalTrials.gg
CompletedNCT02764359Updated Nov 3, 2026Results posted

Study of Obese Patients Comparing Two Vancomycin Loading Dose Regimens

An interventional study of IV vancomycin in Infection, Sepsis and Obesity, sponsored by CAMC Health System. Completed at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Primary conditionSepsisRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Sepsis
Why
  1. The study's listed conditions name Sepsis, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by CAMC Health System · Not applicable, Interventional, and Treatment

How we know

Updated Oct 1, 2026Now CompletedResults posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 517 studies in Sepsis with a site in United States — 74 open to participants now, 99 under way, 3 of them phase 3. Sepsis · United States.

Enrollment
162nd of 310
76 · median 84
Started
2016
with 22 others
No phase
140 of 517
22 open now
Registered
248th of 517
by date

Among the 517 studies in Sepsis with a site in United States, this one is the 162nd largest by enrollment of the 310 interventional ones that give a count, is one of 23 that started in 2016, is one of 140 with no phase, and was the 248th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

74 of the 517 studies in Sepsis with a site in United States are open now. Recruiting first, the newest first:

69 more — sign in →

All 74 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 517 studies in Sepsis with a site in United States, or all of them as a file.
02

Study summary

Obesity alters the movement through the body of several antibiotics, including vancomycin. Based on literature to date, total body weight should be used to determine dosages and shorter dosing intervals may be needed. However, hospitals have different approaches to managing vancomycin in this patient population. The most common example is not exceeding a dose of 2,000mg of vancomycin at one time in these patients. However, some institutions including the Charleston Area Medical Center do not have a set maximum one time dose. To date, a study has not been done comparing two different dosing regimens in obese patients to determine if having a maximum dose cap is beneficial.

This research study is attempting to add to the limited existing body of literature regarding vancomycin dosing in obese patients. The investigators hypothesize that optimizing the initial or loading vancomycin dose that obese patients receive will decrease the time to target concentrations. For this study, obese adult patients will be randomized to receive either 1) a loading dose of 20 mg/kg with a maximum dose up to 2,000mg OR 2) a loading dose of 20 mg/kg with a maximum dose of up to 4,000mg. The study's primary aim is to determine differences in the time needed to achieve target vancomycin concentrations and the occurrence of adverse events.

03

Conditions studied

  • Infection
  • Sepsis
  • Obesity

Browse trials for

04

In context

Sepsis Reclassified

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

This study's enrollment of 76 is below the median of 102 across 1,169 interventional studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

CAMC Health System is the lead sponsor of 47 studies on the registry; 3 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

Compared within Sepsis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥18 years of age who present to the Charleston Area Medical Center-Memorial Hospital Emergency Department
  • Weight >100kg
  • Infection requiring intravenous vancomycin and admission to Charleston Area Medical Center-Memorial Hospital

Exclusion criteria

Exclusion Criteria:

  • Any patient \<18 years of age
  • Patients on dialysis or with unstable renal function (a change of >0.5 mg/dL in SCr concentration in patients with a SCr of \<2 mg/dL or a 20% change in SCr in patients with a SCr of ≥2 mg/dL)
06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    IV Vancomycin loading dose- higher

    IV Vancomycin loading dose: 20 mg/kg with a maximum dose of 4,000mg

    Drug: IV vancomycin

  • Experimental
    IV Vancomycin loading dose- lower

    IV Vancomycin loading dose: 20 mg/kg with a maximum dose of 2,000mg

    Drug: IV vancomycin

Interventions

  • DrugVancomycinStudies of VancomycinVancomycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    IV vancomycin for the treatment of infection. Following the vancomycin loading dose, vancomycin dosing will be at the discretion of the pharmacist and attending physician and will follow standard of care.

07

What researchers measure

Primary outcomes

  1. Time to Attain Therapeutic Vancomycin Concentrations.

    Time to attain therapeutic vancomycin concentrations was measured in hours. Therapeutic vancomycin concentrations were set as 15-20 mg/L in patients with serious, documented Gram-positive infections (e.g., endocarditis, meningitis, pneumonia, osteomyelitis), while in patients with a lower risk of Gram-positive infections (e.g., pyelonephritis, skin/tissue structured infections), therapeutic vancomycin concentrations were defined as 10-15 mg/L.

    Time frame: Time Frame: 20 days

Secondary outcomes

  1. Number of Participants With Reported Adverse Events (AE)

    Red Man's syndrome: pruritus and erythematous rash involving the face, neck, and upper torso. Red Man's syndrome is an older term for vancomycin flushing syndrome (VFS). Nephrotoxicity: increase in serum creatinine (SCr) by 0.5 mg/dL or 50% from baseline on two consecutive measurements.

    Time frame: 48 hours post initial vancomycin dose

  2. Examine the Pharmacokinetic Parameter of Elimination Rate Constant (ke) Following the Loading Vancomycin Dose

    These measurements assessed the elimination rate constant of vancomycin between the two treatment regimens. Two elimination rate constants were assessed: Elimination constant at 7.5-hour trough level and Elimination constant at initial trough level.

    Time frame: 12 hours

  3. Intensive Care Unit Length of Stay

    The duration of time participants spent in the intensive care unit (ICU) during their hospitalization. This outcome measures the total number of days spent in the ICU, from ICU admission to discharge from ICU.

    Time frame: 30 days

  4. Hospital Length of Stay

    The total duration of hospitalization, measured from the time of hospital admission to discharge.

    Time frame: 60 days

  5. In-hospital Mortality

    The percentage of participants that died during their hospital stay. This measure assesses the mortality rate from the time of hospital admission until discharge or death.

    Time frame: 60 days

08

Results

Posted Oct 1, 2026
Limitations and caveats
Limitations include the single-center design and exclusion of patients with unstable renal function, which may limit generalizability. The study period's overlap with COVID-19 may have affected patient demographics and protocols, leading to variability in vancomycin level timing. Not all confounders, such as other medications, were analyzed. Lastly, randomization was limited to the initial vancomycin dose, with further doses determined by the admitting physician.

Participant flow

Participant flow — Overall Study
MilestoneIV Vancomycin Loading Dose- HigherIV Vancomycin Loading Dose- Lower
Started3739
Completed3433
Not completed36
Withdrew: Length of stay less than 24 hours12
Withdrew: Elevated serum creatinine post-consent10
Withdrew: Non-randomized dose01
Withdrew: Incomplete consent documentation13

Outcome measures

PrimaryTime to Attain Therapeutic Vancomycin Concentrations.

Time to attain therapeutic vancomycin concentrations was measured in hours. Therapeutic vancomycin concentrations were set as 15-20 mg/L in patients with serious, documented Gram-positive infections (e.g., endocarditis, meningitis, pneumonia, osteomyelitis), while in patients with a lower risk of Gram-positive infections (e.g., pyelonephritis, skin/tissue structured infections), therapeutic vancomycin concentrations were defined as 10-15 mg/L.

Time frame:
Time Frame: 20 days
Reported as:
Median · hours
Time to Attain Therapeutic Vancomycin Concentrations.
hoursIV Vancomycin Loading Dose- HigherIV Vancomycin Loading Dose- Lower
Time to Attain Therapeutic Vancomycin Concentrations.26.2 (7.8 to 180.8)16.6 (4.6 to 457.6)
SecondaryNumber of Participants With Reported Adverse Events (AE)

Red Man's syndrome: pruritus and erythematous rash involving the face, neck, and upper torso. Red Man's syndrome is an older term for vancomycin flushing syndrome (VFS). Nephrotoxicity: increase in serum creatinine (SCr) by 0.5 mg/dL or 50% from baseline on two consecutive measurements.

Time frame:
48 hours post initial vancomycin dose
Reported as:
Number · Number of Participants with AE
Number of Participants With Reported Adverse Events (AE)
Number of Participants with AEIV Vancomycin Loading Dose- HigherIV Vancomycin Loading Dose- Lower
Red man syndrome/ vancomycin flushing syndrome10
Nephrotoxicity40
SecondaryExamine the Pharmacokinetic Parameter of Elimination Rate Constant (ke) Following the Loading Vancomycin Dose

These measurements assessed the elimination rate constant of vancomycin between the two treatment regimens. Two elimination rate constants were assessed: Elimination constant at 7.5-hour trough level and Elimination constant at initial trough level.

Time frame:
12 hours
Reported as:
Mean · 1/hours
Examine the Pharmacokinetic Parameter of Elimination Rate Constant (ke) Following the Loading Vancomycin Dose
1/hoursIV Vancomycin Loading Dose- HigherIV Vancomycin Loading Dose- Lower
Elimination constant at 7.5-hour trough level0.17 ± 0.090.26 ± 0.12
Elimination constant at initial trough level0.39 ± 0.180.49 ± 0.21
SecondaryIntensive Care Unit Length of Stay

The duration of time participants spent in the intensive care unit (ICU) during their hospitalization. This outcome measures the total number of days spent in the ICU, from ICU admission to discharge from ICU.

Time frame:
30 days
Reported as:
Median · days
Intensive Care Unit Length of Stay
daysIV Vancomycin Loading Dose- HigherIV Vancomycin Loading Dose- Lower
Intensive Care Unit Length of Stay0.0 (0.0 to 16.0)0.0 (0.0 to 22.0)
SecondaryHospital Length of Stay

The total duration of hospitalization, measured from the time of hospital admission to discharge.

Time frame:
60 days
Reported as:
Median · days
Hospital Length of Stay
daysIV Vancomycin Loading Dose- HigherIV Vancomycin Loading Dose- Lower
Hospital Length of Stay6.5 (2.0 to 24.0)6.0 (0.0 to 59.0)
SecondaryIn-hospital Mortality

The percentage of participants that died during their hospital stay. This measure assesses the mortality rate from the time of hospital admission until discharge or death.

Time frame:
60 days
Reported as:
Count of participants · Participants
In-hospital Mortality
ParticipantsIV Vancomycin Loading Dose- HigherIV Vancomycin Loading Dose- Lower
In-hospital Mortality10

Adverse events

Collected over Adverse events were collected systematically through renal function monitoring at baseline, 24, and 48 hours post-vancomycin. Nephrotoxicity was defined as a 0.5 mg/dL or 50% rise in serum creatinine. Vancomycin Flushing Syndrome was tracked based on symptoms like rash and pruritus. All-cause mortality was recorded through the hospital stay, up to 60 days. Data were collected prospectively according to the protocol.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IV Vancomycin Loading Dose- Higher1/34 (2.9%)4/34 (11.8%)0/34 (0%)
IV Vancomycin Loading Dose- Lower0/33 (0%)0/33 (0%)0/33 (0%)
Most frequent serious events
Most frequent serious events
EventIV Vancomycin Loading Dose- HigherIV Vancomycin Loading Dose- Lower
NephrotoxicityRenal and urinary disorders4/340/33
Red man's/Vancomycin flushing syndrome (VFS)Skin and subcutaneous tissue disorders1/340/33

Baseline characteristics

The baseline analysis population includes all participants who completed the study in each arm. No deviations in the baseline population occurred, and the analysis was based solely on participants, with no additional unit-based contributions.

Age, Categorical
Age, Categorical(Participants)IV Vancomycin Loading Dose- HigherIV Vancomycin Loading Dose- LowerTotal
<=18 years000
Between 18 and 65 years262248
>=65 years81119
Age, Continuous
Age, Continuous(years)IV Vancomycin Loading Dose- HigherIV Vancomycin Loading Dose- LowerTotal
Mean53.5 ± 13.760.0 ± 12.056.7 ± 13.2
Sex: Female, Male
Sex: Female, Male(Participants)IV Vancomycin Loading Dose- HigherIV Vancomycin Loading Dose- LowerTotal
Female192342
Male151025
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IV Vancomycin Loading Dose- HigherIV Vancomycin Loading Dose- LowerTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American213
White323264
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)IV Vancomycin Loading Dose- HigherIV Vancomycin Loading Dose- LowerTotal
United States343367
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/meters(squared))IV Vancomycin Loading Dose- HigherIV Vancomycin Loading Dose- LowerTotal
Median41.5 (31.1 to 83.2)42.3 (30.6 to 97.9)42.0 (30.6 to 97.9)
09

Study locations

1 site
  • CAMC Health Systems
    Charleston, West Virginia 25304, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Apr 2024, 92 months.

Results were first posted in Oct 2026, 2 years 6 months after primary completion.

Of 303 non-industry interventional studies with no phase under Sepsis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's 92 months is above that.

Counting every sponsor, half of 326 studies reached it within 22 months; a quarter within 11 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Jan 2021 → Apr 2024 and completion Jan 2021 → Apr 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2016
First posted
May 6, 2016
StartActual
Aug 1, 2016
Primary completionActual
Apr 1, 2024was Jan 2021
CompletionActual
Apr 1, 2024was Jan 2021
Results first posted
Oct 1, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 1, 2026
Results
Results posted
posted Oct 1, 2026
Primary completion
Jan 22, 2021→Apr 1, 2024 (actual)
Oct 1, 2026
Study completion
Jan 22, 2021→Apr 1, 2024 (actual)
Oct 1, 2026
Enrollment
128 (estimated)→76 (actual)
Oct 1, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedTime to attain therapeutic vancomycin concentrationsAttain Therapeutic Vancomycin Concentrations.Time frame: < 7 days → Time Frame: 20 days
Oct 1, 2026
Secondary outcomes
4 edited, 1 added, 2 removed
What changed in the outcomes
  • EditedExamine the pharmacokinetic parameterPharmacokinetic Parameter of elimination rate constantElimination Rate Constant (ke) followingFollowing the loading vancomycin doseLoading Vancomycin DoseTime frame: 12 hours
  • EditedIntensive care unit lengthCare Unit Length of stayStayTime frame: 30 days
  • EditedHospital lengthLength of stayStayTime frame: 30 days → 60 days
  • EditedIn-hospital mortalityMortalityTime frame: 30 days → 60 days
  • AddedNumber of Participants With Reported Adverse Events (AE)Time frame: 48 hours post initial vancomycin dose
  • RemovedReported adverse eventsTime frame: 48 hours post initial vancomycin dose
  • RemovedExamine the pharmacokinetic parameter of volume of distribution (Vd) following the loading vancomycin doseTime frame: 12 hours
Oct 1, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 2 other changes: verification date and responsible party
  2. Oct 1, 2026
    Status unknown→Completed
    Results posted
    Primary completion Jan 22, 2021→Apr 1, 2024 (now actual)
    Study completion Jan 22, 2021→Apr 1, 2024 (now actual)
    Enrollment 128 (estimated)→76 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedTime to attain therapeutic vancomycin concentrationsAttain Therapeutic Vancomycin Concentrations.Time frame: < 7 days → Time Frame: 20 days
    Secondary outcomes 4 edited, 1 added, 2 removed
    What changed in the outcomes
    • EditedExamine the pharmacokinetic parameterPharmacokinetic Parameter of elimination rate constantElimination Rate Constant (ke) followingFollowing the loading vancomycin doseLoading Vancomycin DoseTime frame: 12 hours
    • EditedIntensive care unit lengthCare Unit Length of stayStayTime frame: 30 days
    • EditedHospital lengthLength of stayStayTime frame: 30 days → 60 days
    • EditedIn-hospital mortalityMortalityTime frame: 30 days → 60 days
    • AddedNumber of Participants With Reported Adverse Events (AE)Time frame: 48 hours post initial vancomycin dose
    • RemovedReported adverse eventsTime frame: 48 hours post initial vancomycin dose
    • RemovedExamine the pharmacokinetic parameter of volume of distribution (Vd) following the loading vancomycin doseTime frame: 12 hours
    + 7 other changes: verification date, responsible party, contact details, site details, data sharing statement, registry notes and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT02764359
Lead sponsor
CAMC Health System
Responsible party
Stephanie Thompson (Study Coordinator, CAMC Health System) — Principal investigator
First posted
May 6, 2016
Start date
Aug 1, 2016
Primary completion
Apr 1, 2024
Completion
Apr 1, 2024
Results posted
Oct 1, 2026
Last update
Nov 3, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vancomycin

Start the discussion